Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Cyclin-Dependent Kinase Inhibitor p21. Found 4 abstracts

Tu Y, Hershman DL, Bhalla K, Fiskus W, Pellegrino CM, Andreopoulou E, Makower D, Kalinsky K, Fehn K, Fineberg S, Negassa A, Montgomery LL, Wiechmann LS, Alpaugh RK, Huang M, Sparano JA. A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. Breast Cancer Res Treat. 2014 Jul;146(1):145-52.
Ariazi EA, Brailoiu E, Yerrum S, Shupp HA, Slifker MJ, Cunliffe HE, Black MA, Donato AL, Arterburn JB, Oprea TI, Prossnitz ER, Dun NJ, Jordan VC. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells. Cancer Res. 2010 Feb;70(3):1184-94.   PMCID: PMC2879282
Cai KQ, Wu H, Klein-Szanto AJ, Xu XX. Acquisition of a second mutation of the Tp53 alleles immediately precedes epithelial morphological transformation in ovarian tumorigenicity. Gynecol Oncol. 2009 Jul;114(1):18-25.   PMCID: PMC2739736
Mu Z, Hachem P, Pollack A. Antisense Bcl-2 sensitizes prostate cancer cells to radiation. The Prostate. 2005 Dec;65(4):331-40.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Cyclin-Dependent Kinase Inhibitor p21

Cyclin-Dependent Kinase Inhibitor p21 pathology genetics Tumor Suppressor Protein p53 Female Flow Cytometry Breast Neoplasms Tumor Cell Line metabolism Quinolines Diethylstilbestrol drug therapy EC 3-4-22 (caspase-3) NIH Research Support-Extramural G1 Phase Neoplasm Staging therapeutic use Neoplastic Cell Transformation re [Radiation Effects] Apoptosis Ovarian Neoplasms administration & dosage Neoplasm DNA 0 (Proto-Oncogene Proteins c-bcl-2) Oligonucleotide Array Sequence Analysis Cell Proliferation EC 3-4-22 (Caspases) Antineoplastic Combined Chemotherapy Protocols Alleles Cyclin-Dependent Kinase Inhibitor p27 Cyclophosphamide Transfection ai [Antagonists & Inhibitors] Antisense) 0 (DNA Tumor Biomarkers bi [Biosynthesis] Proto-Oncogene Proteins c-bcl-2 Prostatic Neoplasms rt [Radiotherapy] Mutation classification Cyclopentanes Drug Administration Schedule EC 3-4-22 (caspase 7) Paclitaxel pa [Pathology] Ki-67 Antigen Reverse Transcriptase Polymerase Chain Reaction th [Therapy] G-Protein-Coupled Receptors im [Immunology] Treatment Outcome Adult 0 (Tumor Suppressor Protein p53) Antisense DNA drug effects Estradiol Coloring Agents Combined Modality Therapy Gene Expression pharmacology 0 (Cyclin-Dependent Kinase Inhibitor p21) Middle Aged Neoplastic Gene Expression Regulation Male ge [Genetics] adverse effects Microdissection Estrogen Receptor alpha Estrogens RNA Interference Calcium Immunoblotting Doxorubicin Histone Deacetylases human) 0 (TP53 protein Non-US Gov't Research Support Signal Transduction Aged Hydroxamic Acids Caspases
Last updated on Thursday, April 02, 2020